# Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT06814067** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma HNSCC

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ivonescimab
- **PROCEDURE:** Surgery
- **RADIATION:** Adjuvant radiotherapy

## Key facts

- **NCT ID:** NCT06814067
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2029-02-10
- **Final completion:** 2030-03-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814067, "Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06814067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*